Future Oncology

Papers
(The H4-Index of Future Oncology is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)
ArticleCitations
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer105
Development of a model to predict the prognosis of esophageal carcinoma based on autophagy-related genes74
The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma70
Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study60
Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe53
Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer50
Urothelial Carcinoma in COVID-19: Lessons From a Pandemic and Their Impact on Clinical Practice49
Crosstalk Between Circrnas and the PI3K/AKT and/or MEK/ERK Signaling Pathways in Digestive Tract Malignancy Progression48
Immunotherapy for Liposarcoma: Emerging Opportunities and Challenges45
Radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma: a meta-regression44
The relationship between VDR polymorphisms and keratinocyte carcinomas: a systematic review and meta-analysis44
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study44
Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma43
Correction41
Can Pretreatment Blood Biomarkers Predict Pathological Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer?41
RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR -mutated NSCLC39
Brain Injury after Cranial Radiotherapy Combined with Immunotherapy for Brain Metastases in Lung Cancer: A Retrospective Study39
Sacituzumab Govitecan: Past, Present and Future of a New Antibody–Drug Conjugate and Future Horizon38
Should One Use the Combination of Abiraterone and Poly(ADP-ribose) Polymerase Inhibitors as First-Line Therapy for all Patients with Metastatic Castration-Resistant Prostate Cancer?37
A Multicenter, Phase Ib/II, Open-Label Study of Tivozanib with Durvalumab in Advanced Hepatocellular Carcinoma (DEDUCTIVE)37
In -Class Transition from Bortezomib-Based Therapy to IRd is an Effective Approach in Newly Diagnosed Multiple Myeloma35
Systematic literature review of the epidemiology of neurotrophic tyrosine receptor kinase positive solid tumor sites33
Results of a survey study on health professionals’ perceptions of tumor boards in Brazil33
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)33
Cost–effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer32
Diagnosis of chondrosarcoma in a noninvasive way using volatile organic compounds in exhaled breath: a pilot study31
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis30
Sex bias phenomenon in oral cancer: an insight29
Predicting Amplification of MYCN using CpG Methylation Biomarkers in Neuroblastoma28
Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib28
A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer28
Barriers and solutions for healthcare professionals to involve patients as partners in oncology research: Project RISE28
DUART: Durvalumab After Radiotherapy in Patients with Unresectable, Stage III NSCLC who are Ineligible for Chemotherapy28
0.056149005889893